Aclaris Therapeutics (ACRS) PT Set at $50.00 by Cantor Fitzgerald

Cantor Fitzgerald set a $50.00 target price on Aclaris Therapeutics (NASDAQ:ACRS) in a research note published on Monday. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other research firms have also recently issued reports on ACRS. Zacks Investment Research cut Aclaris Therapeutics from a buy rating to a hold rating in a research note on Wednesday, October 11th. ValuEngine cut Aclaris Therapeutics from a hold rating to a sell rating in a research note on Tuesday, September 12th. Finally, BidaskClub upgraded Aclaris Therapeutics from a sell rating to a hold rating in a research note on Friday, December 29th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $39.20.

Aclaris Therapeutics (ACRS) opened at $25.42 on Monday. Aclaris Therapeutics has a one year low of $21.32 and a one year high of $33.25. The stock has a market capitalization of $762.51 and a price-to-earnings ratio of -11.77.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.86) by $0.23. The firm had revenue of $0.68 million for the quarter, compared to the consensus estimate of $2.00 million. sell-side analysts forecast that Aclaris Therapeutics will post -2.59 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC bought a new stake in Aclaris Therapeutics in the third quarter valued at $142,000. Point72 Asset Management L.P. lifted its stake in Aclaris Therapeutics by 3.5% in the third quarter. Point72 Asset Management L.P. now owns 892,298 shares of the biotechnology company’s stock valued at $23,030,000 after buying an additional 29,896 shares during the last quarter. Highbridge Capital Management LLC bought a new stake in Aclaris Therapeutics in the third quarter valued at $2,581,000. Alyeska Investment Group L.P. lifted its stake in Aclaris Therapeutics by 85.2% in the third quarter. Alyeska Investment Group L.P. now owns 467,884 shares of the biotechnology company’s stock valued at $12,076,000 after buying an additional 215,201 shares during the last quarter. Finally, Boothbay Fund Management LLC lifted its stake in Aclaris Therapeutics by 60.3% in the third quarter. Boothbay Fund Management LLC now owns 20,711 shares of the biotechnology company’s stock valued at $535,000 after buying an additional 7,791 shares during the last quarter. Institutional investors own 92.02% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Aclaris Therapeutics (ACRS) PT Set at $50.00 by Cantor Fitzgerald” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.com-unik.info/2018/01/11/aclaris-therapeutics-acrs-pt-set-at-50-00-by-cantor-fitzgerald.html.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit